|
- Efficacy of Bempedoic Acid, Novel Treatment for Elevated LDL . . .
By Anthony Rice Bempedoic acid is a novel non-statin drug produced by Esperion Therapeutics to treat hypercholesterolemia, elevated levels of low-density lipoprotein (LDL) cholesterol in the blood 1 In the double-blind, placebo-controlled, phase 3 2022 CLEAR Outcomes trial conducted by Esperion, bempedoic acid treatment was associated with reductions in major adverse cardiovascular events
- National Center for Biotechnology Information
We would like to show you a description here but the site won’t allow us
- Bempedoic Acid: The Statin Alternative for Lowering Cholesterol
Learn how bempedoic acid lowers cholesterol without the muscle side effects of statins See who it's for, how it works, and clinical trial results
- Comparative Cardiovascular Benefits of Bempedoic Acid and . . .
Background In the CLEAR (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) Outcomes trial, treatment of statin-intolerant patients with bempedoic acid produced a 21% decrease in low-density lipoprotein cholesterol (LDL-C) relative to placebo and a 13% relative reduction in the risk of major adverse cardiovascular events
- Bempedoic acid in the management of lipid disorders and . . .
Bempedoic acid, the first in-class inhibitor of ATP-citrate lyase presents a new approach to lipid-lowering therapy By reducing the endogenous production of cholesterol, upstream of the rate-limiting enzyme HMG-CoA-reductase, i e , the target of statins, bempedoic acid reduces circulating plasma concentrations of low-density lipoprotein cholesterol (LDL-C), and major adverse CVD events (MACE
- Reshaping Dyslipidaemia Treatment with Bempedoic Acid—A . . .
Dyslipidaemia is one of the main causes of atherosclerotic cardiovascular disease (ASCVD) worldwide Although statins remain the cornerstone of lipid-lowering therapy, many patients do not achieve optimal target levels of low-density lipoprotein cholesterol (LDL-C) due to intolerance or inadequate response Bempedoic acid, an oral ATP citrate lyase inhibitor, provides a liver-specific
- Effect of Bempedoic Acid vs Placebo Added to Maximally . . .
Key Points Question To what extent does bempedoic acid lower low-density lipoprotein cholesterol (LDL-C) levels in patients at high cardiovascular risk who have ongoing hypercholesterolemia, despite the use of maximally tolerated lipid-lowering therapy? Findings In this clinical trial that included 779 randomized patients, the addition to stable background lipid-lowering therapy of bempedoic
- Comprehensive review of statin-intolerance and the practical . . .
Bempedoic acid (BA), an ATP citrate lyase inhibitor, decreases hepatic generation of cholesterol, upregulates low-density lipoprotein (LDL) receptor expression in the liver, and eventually clears circulating LDL-cholesterol from the blood Multiple randomized clinical trials studying BA demonstrate a reduction in LDL levels by 17–28 % in SI
|
|
|